Skip to main content

Table 2 Dose reductions and dose intensity

From: Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity

Chemotherapy Dose reduction at initiation, no (%) Dose reduction after initiation, no (%) Median relative dose intensity (%)a
Nab-paclitaxel 28 (100) 10 (35.7) 57.5
Gemcitabine 13 (46.4) 15 (53.6) 62.4
  1. aRelative dose intensity is the proportion of the administered cumulative dose relative to the planned cumulative dose of G 1000 mg/m2 and Nab-P 125 mg/m2 days 1, 8, and 15 every 4 weeks